Zevra Therapeutics, Inc. · NASDAQ:ZVRA
Zevra Therapeutics — Kempharm — Corporate Update (September 2019)
12 slides from Zevra Therapeutics's corporate update, Sep 4, 2019
Slide 1: KP415/KP484 License Agreement with Gurnet Point Capital
September 4, 2019 KP415/KP484 License Agreement with Gurnet Point Capital Exhibit 99.2
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation contains forward-looking statements, including statements about any royalty or milestone payments under our license agreement, the exchange of any future principal under our exchange agreement, our plans to develop and commercializ
Slide 3: Call Participants
Travis Mickle, Ph.D. – President & Chief Executive Officer R. LaDuane Clifton, CPA – Chief Financial Officer, Secretary & Treasurer Gordon K. “Rusty” Johnson – Chief Business Officer KP415/KP484 License Agreement Call Participants
Slide 4: KP415/KP484 Collaboration and License Agreement
KP415/KP484 Collaboration and License Agreement KemPharm has entered into a definitive collaboration and license agreement with an affiliate of Gurnet Point Capital (GPC) Up to a total of $493M in upfront, regulatory, development and sales milestone payments; plus royalty percentages of up to mid-20
Slide 5: Summary of Deal Terms
Summary of Deal Terms Upfront cash $10M, as well as reimbursement of certain pre-approval development costs for KP415 Development costs and activities Licensee covers development costs for KP415 post-approval, KP484, and if added, KP879 and KP922 KemPharm manages development activities Regulatory mi
Slide 6: Gurnet Point Capital
Gurnet Point Capital GPC is a healthcare fund that invests long-term capital into life sciences and medical technology companies across all stages of project development Founded by Ernesto Bertarelli, former CEO of Serono, SA, and led by Christopher Viehbacher, Managing Partner and former CEO and bo
Slide 7: The ADHD and ER Methylphenidate Market Opportunity
The ADHD and ER Methylphenidate Market Opportunity ~$12 billion ADHD market with prescription growth of >4% year-over-year The branded portion of the ADHD market was ~$6 billion in 2018 and more than 95% of these branded prescriptions are for extended release Methylphenidate (MPH) accounted for appr
Slide 8: KP415 and KP484 Product Overviews
KP415 and KP484 Product Overviews Prodrug of d-MPH (SDX) with extended release properties, co-formulated with IR d-MPH Potential features and benefits: Once-daily dosing Earlier onset, long duration Lower abuse potential Patient-friendly dosage form Potential to be first MPH product approved for pre
Slide 9: KP879 and KP922 Product Overviews
KP879 and KP922 Product Overviews Stand-alone formulation of prodrug of d-MPH (SDX) Potential to be the first approved treatment option for Stimulant Use Disorder (SUD) Very gradual onset of blood concentrations of released d-MPH followed by sustained release Low oral, IN, and IV abuse potential May
Slide 10: Deerfield Debt Exchange Agreement
Deerfield Debt Exchange Agreement KemPharm has simultaneously entered into debt amendment and exchange agreement with Deerfield Exchange agreement reduces long-term debt by up to $30M and reduces the interest rate on senior debt to 6.75% Immediately, $3M of the 2021 Notes held by Deerfield have been
Slide 11: KemPharm Next Steps
KemPharm Next Steps KP415 Work with GPC on review and NDA submission, expect to file in 2019 PDUFA date in 2020 based on anticipated NDA submission date KP484 Work with GPC to review and finalize the product development plan, expect to commence development following KP415’s NDA filing APADAZ Work wi
Slide 12: KP415/KP484 License Agreement with Gurnet Point Capital
September 4, 2019 KP415/KP484 License Agreement with Gurnet Point Capital